Altum Pharmaceuticals secures new financing

Photo of author

By Ted Liu

Altum Pharmaceuticals Inc. has closed a new round of financing, raising $[mepr-active rule=”374″ ifallowed=”hide”]#Research Note – Subscribers ONLY – where and how did you get your news? Subscribe today to see our research on this and all other subscriber ONLY news. Be informed!#[/mepr-active][mepr-active rule=”374″]1,292,500 in two tranches through the issuance of 1,034,000 common shares at $1.25 per share from 26 investors from BC, Alberta and Saskatchewan. The second tranche closed on March 26, 2018. The company has previously raised $2,613,171.60 through the issuance of 2,390,760 common shares priced $1.05-$1.10 per share. 26 Investors from BC, Alberta and USA participated in the financing which also closed in two tranches in February 2018.

Altum Pharmaceuticals is led by Ahmad Doroudian (CEO & Chairman), Haneef Esmail (Director), Moira Ong (CFO), Patrick Frankham (COO).[/mepr-active]

Vancouver based Altum Pharmaceuticals Inc. is a private biopharmaceutical company engaged in clinical and commercial development of novel natural and pharmaceutical compounds, to treat cancer and autoimmune disorders. Altum focuses on development and acquisition of novel products specializing on the commercialization of existing products for cancer and diseases mediated by acute and chronic inflammatory reactions.

photo credit: Altum Pharmaceuticals